Symbiotec Pharmalab Ltd EPS

Symbiotec Pharmalab Ltd EPS

Image

Symbiotec Pharmalab Ltd

NSE: SYMBIOTEC

EPS

₹ 17.95

Last updated on: Sep 29, 2026

Key Highlights

  • The Earning per Share of Symbiotec Pharmalab Ltd is ₹ 17.95 as of 29 Sep 26 The earning per share of Symbiotec Pharmalab Ltd changed from ₹ 5.37 to ₹ 2.24 over 3 quarters. This represents a CAGR of -68.83% .

Historical Earning per Share of Symbiotec Pharmalab Ltd

No data available

* All values are in ₹

Company Fundamentals for null

Market Cap

7,353 Cr

EPS

18.0

P/E Ratio (TTM)

63.8

P/B Ratio (TTM)

5.7

Day’s High

1186.75

Day’s Low

1138.65

DTE

0.3

ROE

9.6

52 Week High

1193.9

52 Week Low

933.8

ROCE

11.6

Market Price of Symbiotec Pharmalab Ltd

1M

1Y

3Y

5Y

Monitoring Symbiotec Pharmalab Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
29 Sep 20261144.35
28 Sep 20261056.75
25 Sep 20261002.55
24 Sep 20261024.95
23 Sep 20261062.15
22 Sep 20261121.25
21 Sep 20261158.45
18 Sep 20261093.25
17 Sep 20261046.8
16 Sep 20261042.5

SWOT Analysis Of Symbiotec Pharmalab Ltd

Strength

1

che

Weakness

0

che

Opportunity

0

che

Threats

0

che

BlinkX Score for Symbiotec Pharmalab Ltd

Asset Value vs Market Value of Symbiotec Pharmalab Ltd

Market Value

₹ 7,353

Asset Value

Value addition

13.3 X

₹ 515

* All values are in ₹ crores

Competitive Comparison of EPS

Company
leftMarket Capright
Symbiotec Pharmalab Ltd7353
Sun Pharmaceutical Industries Ltd446276
Divis Laboratories Ltd251531
Torrent Pharmaceuticals Ltd186957
Zydus Lifesciences Ltd119222
Cipla Ltd111729

Historical Market Cap of Symbiotec Pharmalab Ltd

No data available

* All values are in ₹ crore

Historical Revenue of Symbiotec Pharmalab Ltd

No data available

* All values are in ₹ crore

Historical EBITDA of Symbiotec Pharmalab Ltd

No data available

* All values are in ₹ crore

Historical Net Profit of Symbiotec Pharmalab Ltd

No data available

* All values are in ₹ crore

Dividend Payout Over Time

No data available

Symbiotec Pharmalab Ltd News Hub

Symbiotec Pharmalab to announce Quarterly Result

Symbiotec Pharmalab will hold a meeting of the Board of Directors of the Company on 21 September 202

Read more

12 Sept 26

Symbiotec Pharmalab posts nearly 53% YoY fall in Q1 PAT

Reported EBIDTA declined by 22.1% year-on-year (YoY) to Rs 45.2 crore while reported EBIDTA margin c

Read more

22 Sept 26

Symbiotec Pharmalab IPO ends with 71.26 times subcription

The initial public offer of Symbiotec Pharmalab received bids for 93,52,49,700 shares as against 1,3

Read more

28 Aug 26

Symbiotec Pharmalab consolidated net profit declines 53.01% in the June 2026 quarter

Net profit of Symbiotec Pharmalab declined 53.01% to Rs 14.06 crore in the quarter ended June 2026 a

Read more

23 Sept 26

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for EPS of null

What is the EPS of Symbiotec Pharmalab Ltd stock?

The Earnings Per Share (EPS) of Symbiotec Pharmalab Ltd is 17.95. An EPS is the amount of net income attributed to each share of a common stock.

How is Symbiotec Pharmalab Ltd EPS calculated?

The EPS of Symbiotec Pharmalab Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Symbiotec Pharmalab Ltd report its EPS?

Symbiotec Pharmalab Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Symbiotec Pharmalab Ltd EPS?

Factors that influence the EPS of Symbiotec Pharmalab Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Symbiotec Pharmalab Ltd EPS growth indicate future performance?

Yes, consistent growth in Symbiotec Pharmalab Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions